218 related articles for article (PubMed ID: 37056930)
1. NUF2 Drives Cholangiocarcinoma Progression and Migration via Inhibiting Autophagic Degradation of TFR1.
Shan J; Jiang W; Chang J; Zhou T; Chen Y; Zhang Y; Wang J; Wang Y; Wang Y; Xu X; Liu S; Shi X; Fan S; Chen R; Li C; Li X
Int J Biol Sci; 2023; 19(5):1336-1351. PubMed ID: 37056930
[TBL] [Abstract][Full Text] [Related]
2. YY1-induced DLEU1/miR-149-5p Promotes Malignant Biological Behavior of Cholangiocarcinoma through Upregulating YAP1/TEAD2/SOX2.
Li J; Jiang X; Xu Y; Kang P; Huang P; Meng N; Wang H; Zheng W; Wang H; Wang Z; Zhong X; Cui Y
Int J Biol Sci; 2022; 18(11):4301-4315. PubMed ID: 35864972
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation.
Chen Y; Xu X; Wang Y; Zhang Y; Zhou T; Jiang W; Wang Z; Chang J; Liu S; Chen R; Shan J; Wang J; Wang Y; Li C; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):265. PubMed ID: 37821935
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-329-mediated PTTG1 downregulation inactivates the MAPK signaling pathway to suppress cell proliferation and tumor growth in cholangiocarcinoma.
Hu ZG; Zheng CW; Su HZ; Zeng YL; Lin CJ; Guo ZY; Zhong FD; Yuan GD; He SQ
J Cell Biochem; 2019 Jun; 120(6):9964-9978. PubMed ID: 30582202
[TBL] [Abstract][Full Text] [Related]
5. MCM2 promotes the proliferation, migration and invasion of cholangiocarcinoma cells by reducing the p53 signaling pathway.
Wang CL; Liu XY; Wang YH; Zhang Z; Wang ZD; Zhou GQ
Yi Chuan; 2022 Mar; 44(3):230-244. PubMed ID: 35307646
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
Hu X; Tan Z; Yang Y; Yang P
J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
[TBL] [Abstract][Full Text] [Related]
7. MORC2 promotes cell growth and metastasis in human cholangiocarcinoma and is negatively regulated by miR-186-5p.
Liao G; Liu X; Wu D; Duan F; Xie X; Wen S; Li Y; Li S
Aging (Albany NY); 2019 Jun; 11(11):3639-3649. PubMed ID: 31180332
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
9. Downregulated circular RNA hsa_circ_0001649 regulates proliferation, migration and invasion in cholangiocarcinoma cells.
Xu Y; Yao Y; Zhong X; Leng K; Qin W; Qu L; Cui Y; Jiang X
Biochem Biophys Res Commun; 2018 Feb; 496(2):455-461. PubMed ID: 29337065
[TBL] [Abstract][Full Text] [Related]
10. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
Deng S; Zhang L; Li J; Jin Y; Wang J
Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
[TBL] [Abstract][Full Text] [Related]
11. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
13. SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1.
Shi AD; Zhao LM; Sheng GL; Zhang GN; Tang YC; Li KS; Zhang ZL
J Cell Mol Med; 2023 Sep; 27(17):2547-2561. PubMed ID: 37488750
[TBL] [Abstract][Full Text] [Related]
14. NUF2 Drives Clear Cell Renal Cell Carcinoma by Activating HMGA2 Transcription through KDM2A-mediated H3K36me2 Demethylation.
Lin J; Chen X; Yu H; Min S; Chen Y; Li Z; Xie X
Int J Biol Sci; 2022; 18(9):3621-3635. PubMed ID: 35813477
[TBL] [Abstract][Full Text] [Related]
15. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner.
Liu Z; Hu C; Zheng L; Liu J; Li K; Li X; Wang Y; Mu W; Chen T; Shi A; Qiu B; Zhang X; Zhang Z; Xu Y
Cell Mol Life Sci; 2022 Aug; 79(9):469. PubMed ID: 35932322
[TBL] [Abstract][Full Text] [Related]
16. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
[TBL] [Abstract][Full Text] [Related]
17. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
Zhang C; Wang Y; Wu G; Sun N; Bai H; Li X; Han S; Zhou H; Qi R; Zhang J
Biol Direct; 2024 Feb; 19(1):16. PubMed ID: 38395908
[TBL] [Abstract][Full Text] [Related]
18. ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation.
Wang Z; Wu S; Wang G; Yang Z; Zhang Y; Zhu C; Qin X
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676763
[No Abstract] [Full Text] [Related]
19. Oncogenic Role of the NFATC2/NEDD4/FBP1 Axis in Cholangiocarcinoma.
Zhao W; Zhao J; Li K; Hu Y; Yang D; Tan B; Shi J
Lab Invest; 2023 Sep; 103(9):100193. PubMed ID: 37285922
[TBL] [Abstract][Full Text] [Related]
20. m
Zheng H; Zhu M; Li W; Zhou Z; Wan X
Liver Int; 2022 May; 42(5):1144-1157. PubMed ID: 35274813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
